Read More Pharma Industry News XyloCor reveals promising 12-month data from Phase 2 Trial of XC001 XyloCor Therapeutics, a clinical-stage biopharmaceutical company focusing on novel gene therapies for cardiovascular diseases, has revealed encouraging 12-month… byPallavi MadhirajuJuly 18, 2023